M. Hoover

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

L. Turka, T. Wickham, Enping Hong, 2021, Cancer Immunology, Immunotherapy.

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

J. Bolognese, H. Quan, I. Bjarnason, 2000, Gut.

Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

J. Bolognese, H. Quan, F. R. Wilson, 1999, Alimentary pharmacology & therapeutics.